Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Incyte Signals Increasing Focus In Dermatology With Villaris Buyout

03 Oct 2022

• By Joseph Haas

Dermatology — Incyte adds to its dermatology portfolio with Villaris acquisition • Source: Shutterstock

Related Content

Patient-Focused Meeting On Vitiligo Could Galvanize R&D As The First Drug Candidates In A Long Time Advance

20 Apr 2021

Equillium Buys Metacrine For Its Cash, Will Outsource Lead Drug Candidate

07 Sep 2022

Incyte Bolsters Dermatology Ambitions With Vitiligo Approval For Topical Ruxolitinib

19 Jul 2022

Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval

22 Sep 2021

Dermatology To Become A Key Franchise For Incyte

15 Dec 2021

Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs

08 Nov 2018

Related Companies

Incyte Corporation

Amgen, Inc.

Provention Bio, Inc.

Calypso Biotech BV

Equillium, Inc.

Additional Topics

M & A Business Strategies Commercial Deals Dermatology BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.